Activated Cancer Therapy Using Light and Ultrasound - A Case Series of Sonodynamic Photodynamic Therapy in 115 Patients over a 4 Year Period

Activated Ca ncer Ther apy ( ACT), al so know n a s Sonodyna mic Phot odynamic Ther apy ( SPDT) i s a nove l therapeutic modality that utilises a non-toxic photosensitive agent with reported ultrasound-activated properties. SPDT has previously demonstrated significant tumour cell inhibition in animal studies. There has been much research into the efficacy of phot odynamic therapy and development in understanding of the underlying mechanism of tumour cytotoxicity. Synergistic ultrasound activation represents a promising development to activated sensitiser therapy, as photo-activation is limited by access and penetrance issues. Ultrasound has been demonstrated to activate a number of sono-sensitive agents allowing the possibility of non-invasive targeted treatment of deeper tumour sites than is currently achievable with photodynamic therapy. Thi s case se ries of 115 pa tients w ith a v ariety of ca ncer di agnoses reports on experiences of this treatment over a 4 year period using sublingual administration of a new dual activation agent, Sonnelux-1, followed by a protocol of LED light and low-intensity ultrasound exposure. Initial clinical observation suggests SPDT is worthy of further investigation a s an ef fective and well to lerated t reatment fo r a wide v ariety o f p rimary and metastatic tumours, including those refractory to chemotherapy. Key Wo rds: Sonodynamic therapy, photodynamic therapy, activated cancer therapy, u ltrasound activated therapy, metastatic cancer, sonnelux-1, dove clinic, sonnemed.